Sorafenib Demonstrates Activity in AML

Christoph Röllig, MD

In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.

At the 2014 American Society of Hematology Annual Meeting, Christoph Röllig, MD, of University Hospital Dresden, Germany, discusses the results of the SORAML trial that tested sorafenib compared with placebo as add-on to standard induction and consolidation treatment in patients with acute myeloid leukemia (AML) aged 18 to 60 years. 

Related Content:

American Society of Hematology Annual Meeting & Exposition (ASH)Hematology
Efstathios Kastritis, MD, on Main Findings From the ANDROMEDA Study in Newly Diagnosed AL Amyloidosis
Efstathios Kastritis, MD, on Implications of Positive Results From the Phase 3 ANDROMEDA Study
Patients With CLL and Other B-Cell Malignancies Benefitted from TG-1701